Puma Biotechnology, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$38.7M
Doctors Paid
9,190
Transactions
37,663
2024 Total
$3.5M
Payment Breakdown by Category
Research$31.0M (80.1%)
Consulting$3.6M (9.3%)
Food & Beverage$801,763 (2.1%)
Travel$610,940 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31.0M | 1,887 | 80.1% |
| Consulting Fee | $3.6M | 969 | 9.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 818 | 6.0% |
| Food and Beverage | $801,763 | 31,188 | 2.1% |
| Travel and Lodging | $610,940 | 2,465 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $314,339 | 132 | 0.8% |
| Grant | $10,000 | 1 | 0.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $5,897 | 7 | 0.0% |
| Education | $2,102 | 196 | 0.0% |
Payments by Type
Research
$31.0M
1,887 transactions
General
$7.7M
35,776 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION | $4.6M | 0 | 300 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NERATINIB (HKI-272) AFTER TRASTUZUMAB IN WOMEN WITH EARLY-STAGE HER-2/NEU OVEREXPRESSED/AMPLIFIED BREAST CANCER | $1.7M | 3 | 112 |
| AN OPEN-LABEL, PHASE 2 BASKET STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC ACTIVATING HER MUTATIONS | $1.7M | 0 | 72 |
| An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors | $1.7M | 0 | 115 |
| An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal | $1.6M | 0 | 86 |
| An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early | $1.6M | 0 | 54 |
| . | $1.4M | 0 | 11 |
| THIS IS AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, MULTINATIONAL, PHASE 2 STUDY | $1.2M | 0 | 119 |
| A STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (ALISCA-LUNG1) | $1.1M | 0 | 177 |
| An Open?Label Study to Characterize the Incidence and Severity of Diarrhea | $1.0M | 0 | 105 |
| BASKET STUDY OF NERATINIB IN PARTICIPANTS WITH SOLID TUMORS HARBORING SOMATIC HER2 OR EGFR EXON 18 MUTATIONS (SUMMIT) | $911,655 | 0 | 9 |
| A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated | $805,972 | 0 | 1 |
| AN OPEN LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION | $756,293 | 0 | 43 |
| AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA | $712,730 | 0 | 34 |
| AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA IN PATIENTS WITH EARLY-STAGE HER2+ BREAST CANCER TREATED WITH NERATINIB AND INTENSIVE LOPERAMIDE PROPHYLAXIS | $630,803 | 0 | 39 |
| A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ | $523,614 | 0 | 36 |
| A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer | $476,857 | 0 | 1 |
| A Phase II Study of Neratinib alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer | $363,238 | 0 | 2 |
| PHASE I STUDY OF THE PAN-ERBB INHIBITOR NERATINIB GIVEN IN COMBINATION WITH EVEROLIMUS, PALBOCICLIB, OR TRAMETINIB IN ADVANCED CANCER SUBJECTS WITH EGFR MUTATION/AMPLIFICATION, HER2 MUTATION/AMPLIFICATION, OR HER3/4 MUTATION OR KRAS MUTATION | $349,363 | 0 | 2 |
| AN OPEN LABEL, PHASE II TRIAL OF PRE-OPERATIVE NERATINIB AND ENDOCRINE THERAPY WITH TRASTUZUMAB IN TRIPLE POSITIVE BREAST CANCERS HCRN-BRE17-141 | $325,650 | 0 | 7 |
| A Study of Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine(NALA) | $301,426 | 0 | 56 |
| ALISERTIB WITH OR WITHOUT FULVESTRANT IN TREATING PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ENDOCRINE RESISTANT BREAST CANCER | $299,864 | 0 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | $298,949 | 1 | 124 |
| A PHASE 2 STUDY OF NERATINIB WITH OR WITHOUT FULVESTRANT IN HER2-POSITIVE, ER-POSITIVE METASTATIC BREAST CANCER | $293,466 | 0 | 3 |
| A Study of Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine in Patients with HER2+ | $286,452 | 0 | 115 |
| IMPACT Profiling in Patients with Advanced Cervix Cancer | $275,250 | 0 | 7 |
| A PHASE II TRIAL OF HKI-272 (NERATINIB), NERATINIB AND CAPECITABINE, AND ADO-TRASTUZUMAB EMTANSINE FOR PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER AND BRAIN METASTASES | $256,160 | 0 | 2 |
| A PHASE II STUDY OF ALISERTIB, AN INVESTIGATIONAL DRUG, IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) | $253,935 | 0 | 13 |
| A STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER (ALISCA-BREAST1) | $253,397 | 0 | 14 |
| Evaluating Neratinib in orthotopic PDX models of breast cancer brain metastases | $232,418 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Gregory Vidal, M.d, M.D | Medical Oncology | Germantown, TN | $18,561 | $0 |
| Ruth O'regan, Md, MD | Hematology & Oncology | Rochester, NY | $18,340 | $0 |
| Andrew Seidman, Md, MD | Medical Oncology | New York, NY | $18,108 | $0 |
| Dr. Kelly Mccann, M.d., Ph.d, M.D., PH.D | Internal Medicine | Santa Monica, CA | $17,755 | $0 |
| Jane Meisel, Md, MD | Hospitalist | Boston, MA | $17,507 | $0 |
| Dr. Hatem Soliman, Md, MD | Hematology & Oncology | Tampa, FL | $16,654 | $0 |
| Sami Diab, Md, MD | Medical Oncology | Aurora, CO | $16,314 | $0 |
| Sramila Aithal, Md, MD | Medical Oncology | Bensalem, PA | $15,082 | $0 |
| Dr. Elyse Lower, Md, MD | Hematology & Oncology | Cincinnati, OH | $14,697 | $0 |
| Miss. Erin Roesch, M.d, M.D | Hematology & Oncology | La Jolla, CA | $12,984 | $0 |
| Kelley Mayden, Aocnp, AOCNP | Nurse Practitioner | Norton, VA | $12,300 | $0 |
| Dr. Elias Obeid, M.d., Mph, M.D., MPH | Hematology & Oncology | Philadelphia, PA | $10,971 | $0 |
| Dr. Steven Isakoff, Md Phd, MD PHD | Hematology & Oncology | Boston, MA | $10,790 | $0 |
| Mark Pegram, M.d, M.D | Internal Medicine | Stanford, CA | $10,528 | $0 |
| Heather Mcarthur, M.d, M.D | Internal Medicine | Dallas, TX | $10,106 | $0 |
| Mohammad Jahanzeb, Md, MD | Hematology & Oncology | Boca Raton, FL | $10,012 | $0 |
| Dr. Sara Tolaney, Md, MD | Internal Medicine | Boston, MA | $9,938 | $0 |
| Lee Schwartzberg, Md, MD | Hematology | Reno, NV | $9,770 | $0 |
| Vincente Valero, M.d, M.D | Medical Oncology | Houston, TX | $9,673 | $0 |
| Aditya Bardia, Md, MD | Medical Oncology | Santa Monica, CA | $9,421 | $0 |
| Mr. Charles Vogel, Md, MD | Medical Oncology | Plantation, FL | $8,874 | $0 |
| Tiffany Traina, Md, MD | Medical Oncology | New York, NY | $8,604 | $0 |
| Dr. April Teitelbaum, Md, MD | Medical Oncology | San Diego, CA | $8,100 | $0 |
| Gabrielle D'amore, Pa-C, PA-C | Physician Assistant | Royal Oak, MI | $8,083 | $0 |
| Paloma Ortiz Fernandez, Fnp-Bc, FNP-BC | Family | San Juan, PR | $7,723 | $0 |
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. has made $38.7M in payments to 9,190 healthcare providers, recorded across 37,663 transactions in the CMS Open Payments database. In 2024, the company paid $3.5M. The top product by payment volume is NERLYNX ($19.9M).
Payments were distributed across 144 medical specialties. The top specialty by payment amount is Medical Oncology ($3.2M to 716 doctors).
Payment categories include: Food & Beverage ($801,763), Consulting ($3.6M), Research ($31.0M), Travel & Lodging ($610,940).
Puma Biotechnology, Inc. is associated with 2 products in the CMS Open Payments database.